BRIEFCURRICULUM VITAE (June 2006)Matthew E. Falagas, M.D., M.Sc.
PERSONAL AIBS office:
Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Str. & Kifissias Ave., 151 23 Marousi, Athens, Greece (www.aibs.gr)
Tel. (+30) 210-68.39.604, Fax (+30) 210-68.39.605,
Mobile tel. (+30) 694-61.10.000 e-mail: [email protected], [email protected]
“Henry Dunant” Hospital, 107 Mesogion Ave., 115 26 Athens, Greece
Tel. (+30) 210-69.72.492, Fax: (+30) 210-69.72.905 e-mail: [email protected] ACADEMIC APPOINTMENTS 02/2006 - contin.
Adjunct Associate Professor of Medicine, Tufts University School ofMedicine, Boston, Massachusetts
Adjunct Assistant Professor of Medicine, Tufts University School ofMedicine, Boston, Massachusetts
Instructor in Medicine, Tufts University School of Medicine, Boston, Massachusetts
HOSPITAL APPOINTMENTS 05/2003 - contin.
Director, Employee Health Clinic, “Henry Dunant” Hospital, Athens, Greece
Director, Infectious Diseases Clinic, “Henry Dunant” Hospital, Athens, Greece
Staff Physician/Admitting privileges, “Hygeia Hospital”, Athens, Greece
GRADUATE EDUCATION 1994 - 1996
MSc, Harvard University, Harvard School of Public Health
MD, Athens University, School of Medicine
PROFESSIONAL TRAINING 1994 - 1996
Clinical and Research Fellow in Infectious Diseases and Geographic Medicine, Department of Medicine, Tufts University School of Medicine, New England Medical Center, Boston, Massachusetts
Clinical Fellow in Infectious Diseases and Geographic Medicine, Department of Medicine, Tufts University School of Medicine, New England Medical Center, Boston, Massachusetts
Senior Resident in Internal Medicine, Tufts University School of Medicine, Newton-Wellesley Hospital, Boston, Massachusetts
Intern and Junior Resident in Internal Medicine, State University of New York (SUNY) at Buffalo, School of Medicine and Biomedical Sciences, Buffalo General Hospital, Buffalo, New York
OTHER PROFESSIONAL EXPERIENCE 2005 - contin.
President of the Executive Board and Director, Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece
President, Alfa HealthCare, Athens, Greece
Regional Medical Advisor, Highway to Health, Radnor, Pensylvania
Private Practice (Internal Medicine-Infectious Diseases), Athens, Greece
Primary Care Physician, National Medical Service, Health Center of
Army Unit Doctor, National Military Service (Greece)
TEACHING EXPERIENCE 2006 - contin.
Adjunct Associate Professor of Medicine, Tufts University School of Medicine, Boston, Massachusetts
Director, Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece
Adjunct Assistant Professor of Medicine, Tufts University School of Medicine, Boston, Massachusetts
Scientific Collaborator, University Department of Medicine, “Hippokratio” Hospital, Athens University School of Medicine
Instructor in Medicine, Tufts University School of Medicine
Clinical Instructor in Medicine, Tufts University School of Medicine
Review courses for Internal Medicine Boards certification examination (organizer and moderator), Newton-Wellesley Hospital, Tufts University School of Medicine, Boston, Massachusetts
Journal club (organizer and moderator), Newton-Wellesley Hospital, Tufts University School of Medicine, Boston, Massachusetts
Assistant Clinical Instructor in Medicine, State University of New York (SUNY) at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, New York
RESEARCH EXPERIENCE 2005 - contin.
Clinical research, Principal Investigator, Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece and “Henry Dunant” Hospital, Athens, Greece
Clinical research, Principal Investigator, Alfa HealthCare, Athens, Greece and “Henry Dunant” Hospital, Athens, Greece
Clinical research, Principal Investigator, “Hygeia” Hospital, Athens, Greece
Clinical research; design, implementation, analysis, and interpretation of clinical studies investigating several researches questions and focusing on cytomegalovirus infections, infections in transplant recipients, nosocomial infections, and infections due to anaerobic bacteria;
Tufts University School of Medicine and Harvard School of Public Health. Mentors: Dr. David Snydman, Professor of Medicine and Pathology, Tufts University School of Medicine, and Director of Clinical Microbiology Laboratory, New England Medical Center. Dr. Alexander Walker, Chairman of Epidemiology, Harvard School of Public Health, Harvard University, Boston, Massachusetts
Cytokines in chronic renal failure, chronic ambulatory peritoneal
dialysis (CAPD), and hemodialysis patients (basic research); Tupper Research Institute, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts.
Mentor: Dr. Charles Dinarello, Professor of Medicine, Pediatrics, and
Molecular Biology, Tufts University School of Medicine.
Parasite-host interactions in human infections with Neisseria gonorrhoeae and Haemophilus influenzae (basic research); State
University of New York (SUNY) at Buffalo, School of Medicine, and
Biomedical Sciences, Buffalo, NY. Mentor: Dr. Michael Apicella, Professor of Medicine, Molecular Biology and Microbiology, SUNY at Buffalo, and Chief of Division of Infectious Diseases.
RESEARCH INTERESTS 1. Polymyxins 2. Antimicrobial resistance 3. Nosocomial infections 4. Acinetobacter infections 5. Infections in immunosuppressed patients 6. Estimates and determinants of research productivity RESEARCH GRANTS 2005
Biomedical research productivity of European countries (principal investigator)
Long-term efficacy and safety of pioglitazone plus metformin versus gliclazide plus metformin in patients with type 2 diabetes mellitus (site principal investigator)
Long-term efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus (site principal investigator)
Foundation of a database of Greek biomedical scientists in diaspora and its introduction in the world wide web (principal investigator)
Comparison of incidence and severity of toxicities of cyclosporine and recipients (co-investigator)
In vitro synergism between trovafloxacin and cefoperazone against Bacteroides fragilis group (co-investigator)
Investigation of synergistic in vitro effect of trovafloxacin with cefoperazone or ceftazidime against Gram negative non-fermenting rods (co-investigator)
Retrospective study examining independent risk factors for development of invasive Candida infections in surgical intensive care unit (SICU) patients (co-investigator)
Outcome of transplantation of solid organs from bacteremic donors (co-investigator)
Bacteriologic study examining the impact of pH on in vitro antimicrobial susceptibility of Bacteroides fragilis (co-investigator)
RESEARCH THESIS "The impact of cytomegalovirus (CMV) on short and long term survival of orthotopic liver transplant recipients" (submitted). Athens University School of Medicine. Mentor: Dr. Dimitrios Trichopoulos, Professor of Epidemiology, Athens University School of Medicine, and Professor of Epidemiology, Harvard School of Public Health. HONORS AND PRIZES 1997 Maxwell Finland Young Investigator Award for Excellence inResearch, Massachusetts Infectious Diseases Society
Research Award (for the study: Cancer incidence after metronidazole use: a matched metronidazole user/non-user study), Amfiaraion Foundation for the Study of Chemotherapeutic Agents, 23rd Panhellenic Medical Conference, Athens, Greece
Edward Kass Award for Clinical Excellence, Massachusetts Infectious Diseases Society
House Staff Award for Excellence in Teaching, The Medical Student Body State University of New York (SUNY) at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, New York
Diploma in Medicine with “Excellence” (Top 5% of class), Athens University School of Medicine
Scholarship, Athens University (1981 contest among candidate students from all Schools and Departments of Athens University)
First Prize, Greek Association of Mathematicians, contest in Mathematics among high school students throughout Greece
DISTINCTIONS 09/2005 - continued Member of the National Faculty of The Core Content Review of Family MEMBERSHIP 1. European Society of Clinical Microbiology and Infectious Diseases 2. Infectious Diseases Society of America 3. American Society for Microbiology 4. Massachusetts Medical Society 5. HIV Medicine Association 6. American Association for the Advancement of Science 7. Athens Medical Society
8. Medical Association of Athens 9. Panhellenic Medical Association LICENSURE AND CERTIFICATION 2001
Certified Diplomate in Infectious Diseases (Greece)
Certified Diplomate in Internal Medicine (Greece)
Certified Diplomate in Infectious Diseases by the American Board ofInternal Medicine (committee of Infectious Diseases) (USA)
Certified Diplomate in Internal Medicine by the American Board ofInternal Medicine (USA)
USA Educational Commission for Foreign Medical Graduates (ECFMG) permanent certificate
COMMITTEES 10/2004 – 12/2005 President, Infection Control Committee, “Henry Dunant” Hospital,
Infection Control Committee, “Henry Dunant” Hospital, Athens, Greece
Education Committee, European Society of Clinical Microbiology and Infectious Diseases
Advisory committee for the affiliation of “Hygeia” Hospital, Athens, Greece, with Partners HealthCare System (Massachusetts General Hospital, Brigham and Women’s Hospital and Dana Farber Cancer Institute), Boston, Massachusetts
External scientific partner of National Organization for Drugs, Athens, Greece
LECTURES (Selection from invited lectures) 02/2006
Effectiveness and safety of polymyxins. 2nd Top Ten on Infections. Inter-disciplinary seminar on infections, Athens, Greece
Therapeutic strategies for Acinetobacter infections. Acinetobacter: an emerging crisis. National Symposium, Oxford, UK
Old antibiotics are back. Meet-the-Expert session. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark
Clinical research on nosocomial infections. 1st Top Ten on Infections. Inter-disciplinary seminar on infections, Athens, Greece
Effectiveness and safety of colistin for the treatment of multi-drug resistant Gram negative bacterial infections: the renaissance of an old antibiotic. Infectious Diseases division research conference. Tufts - New England Medical Center, Boston, Massachusetts
Management of multidrug resistant bacterial infections. 3rd European Society of Clinical Microbiology and Infectious Diseases (ESCMID) School, Athens, Greece
Tuberculous peritonitis. Clinicopathologic Conference. “Laiko” Hospital, Department of Medicine, Athens University School of Medicine, Athens, Greece
Developments in the management of community acquired infections. Medical Association of Karditsa, Karditsa, Greece
Management of infectious diseases. 1st European Society of Clinical Microbiology and Infectious Diseases (ESCMID) School, Lausanne, Switzerland
Protective measures against bioterrorism. Seminar. “Hygeia” Hospital, Athens, Greece
Differential diagnosis of pulmonary infiltrates. 17th annual pulmonary diseases seminar of the Hellenic Pulmonary Society, Athens, Greece
Management of patients with septic shock. General Hospital of Limassol, Cyprus
Increasing antimicrobial resistance: a major threat to humanity. Harvard Medical International-Partners-“Hygeia” Hospital Conference, Athens, Greece
Antimicrobial agents in the elderly: theoretical issues and clinical problems. 4th Panhellenic conference of the Hellenic Society for Infectious Diseases, Athens, Greece
Modern management of neutropenic patients with fever. Panhellenic Combined Conference of Greek Pain Society and Greek Society of Palliative Care, Athens, Greece
Viral hepatitis. 7th Scientific Conference of Hygeia Hospital, Karpenisi, Greece
The continuing medical education (CME) credit hour system in the USA: How does it work? 24th Annual Panhellenic Medical Conference, Athens, Greece
Fever of unknown origin: Clinicopathologic Conference, Depatrment of Medicine, “Sotiria” Hospital, Athens University School of Medicine, Athens, Greece
Metronidazole and cancer. Progress in research conference. New England Medical Center, Boston, Massachusetts
Controversial issue: Are immunoglobulins useful for prevention and treatment of viral and bacterial infections in transplantation? Conference on Pulmonary Infections in Organ Transplant Recipients, Milan, Italy
Is cytomegalovirus an immunopathological condition? Conference on Pulmonary Infections in Organ Transplant Recipients, Milan, Italy
Infections in transplant recipients. 4th world biomedical conference of the Hellenic diaspora, Nicosia, Cyprus
The impact of cytomegalovirus on short and long term survival of liver transplant recipients. Progress in research conference. New England Medical Center, Boston, Massachusetts
Recurrent cytomegalovirus disease in solid organ transplant recipients. Symposium on Controversies in Transplant Infection, Tucson, Arizona
Differential diagnosis of common symptoms in patients infected with the human immunodeficiency virus (HIV). Department of Medicine Conference, Saint Elizabeth’s Hospital of Boston, Tufts University School of Medicine
HIV and AIDS. Medical Grand Rounds, Department of Medicine, Newton-Wellesley Hospital, Tufts Univ. School of Medicine, Boston
ORGANIZATION OF INTERNATIONAL MEDICAL CONFERENCES 09/2005
4th conference of the International Society for the Prevention of Tobacco Induced Diseaes (ISPTID), Athens, Greece (co-chair of the Scientific Committee)
3rd School of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID), Athens, Greece (local organizer and course director)
Obesity and complications: a 3-day seminar. Inter-University European seminar, Athens, Greece (local organizer and course director)
ORGANIZATION OF NATIONAL MEDICAL CONFERENCES 02/2006
2nd Top Ten on Infections: a 3-day Inter-disciplinary seminar with interactive sessions, Athens, Greece (seminar co-organizer and director)
1st Top Ten on Infections: a 3-day Inter-disciplinary seminar with interactive sessions, Athens, Greece (seminar co-organizer and director)
ORGANIZING COMMITTEE OF INTERNATIONAL MEDICAL CONFERENCES 05/2006
19th European Congress on Surgical Infections, Surgical Infection Society – Europe, Athens, Greece
REVIEWER IN PEER-REVIEWED JOURNALS 1. American Journal of Managed Care 2. Annals of Internal Medicine 3. BMC Infectious Diseases 4. BMC Public Health 5. Chest 6. Clinical Infectious Diseases 7. Clinical Microbiology and Infection 8. Clinical Orthopedics and Related Research 9. Critical Care Medicine 10. Fundamental and Clinical Pharmacology 11. Journal of Chemotherapy 12. Journal of Antimicrobial Chemotherapy 13. Lancet 14. Lancet Infectious Diseases 15. Occupational and Environmental Medicine 16. Pediatrics International 17. Pediatric Nephrology 18. PharmacoEconomics 19. Trials REVIEWER IN THE ABSTRACT SELECTION PROCESS FOR CONFERENCES 1. 16th European Conference of Clinical Microbiology and Infection Diseases (ECCMID),
2. 15th European Conference of Clinical Microbiology and Infection Diseases (ECCMID),
3. 14th European Conference of Clinical Microbiology and Infection Diseases (ECCMID),
4. Athens Medical Society, “P. Papastamatis” award, 2002 EDITOR 1. Tobacco Induced Diseases (TID) GUEST EDITOR 1. Clinical Orthopedics and Related Research (CORR), symposium on spinal infection (03/2006) CITATIONS My papers (author or co-author) have been cited about 1,100 times in papers published in journals indexed by Thomson Scientific (Institute of Scientific Information -ISI). [Source: Thomson Scientific (Institute of Scientific Information), Philadelphia, Pennsylvania - checked on 07/April/2006]. PUBLICATIONS: ORIGINAL RESEARCH PAPERS (PEER-REVIEWED)
1. Falagas ME, Rosmarakis ES, Rellos K, Michalopoulos A, Samonis G, Prapas SN.
Microbiologically documented nosocomial infections after coronary artery bypass surgery without cardiopulmonary bypass (off-pump). J Thorac Cardiovasc Surg (in press).
2. Falagas ME, Bliziotis IA, Soteriades ES. A prospective study of services utilization of a
hospital-based Employee Health Clinic. Med Sci Monit (in press).
3. Falagas ME, Karveli EA. World Wide Web resources on antimicrobial resistance. Clin
4. Falagas ME, Rosmarakis ES, Avramopoulos I, Vakalis N. Streptococcus agalactiae
infections in non-pregnant adults: single center experience of a growing clinical problem. Med Sci Monit (in press).
5. Panos GZ, Karydis I, Velakoulis SE, Falagas ME. Multi-skeletal Pneumocystis jiroveci
(carinni) in an HIV seropositive patient. Int J STD AIDS (in press).
6. Korres DS, Papagelopoulos PJ, Zahos KA, Kolia MD, Poulakou GG, Falagas ME.
Multifocal spinal and extra-spinal Mycobacterium chelonae osteomyelitis in a renal transplant recipient. Transpl Infect Dis (in press).
7. Falagas ME, Koletsi PK, Kopterides P, Michalopoulos A.Risk factors for isolation of
polymyxin-only susceptible strains among patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother (in press).
8. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and
safety of intravenous colistin for the treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria. Eur J Clin Microbiol Infect Dis (in press).
9. Athanasiou S, Matthaiou DK, Falagas ME. Vaginal mesh infectiondue to Bacteroides melaninogenicus: a case report of another emerging foreign body related infection. Scand J Infect Dis (in press).
10. Falagas ME, Siempos II, Tsakoumis I. Cure of persistent, post-appendectomy Klebsiella pneumoniae septicemia with continuous intravenous administration of meropenem. Scand J Infect Dis (in press).
11. Falagas ME, Kasiakou SK, Nikita D, Morfou P, Georgoulias G, Rafailidis PI. Secular trends
of antimicrobial resistance of blood isolates in a newly founded Greek hospital. BMC Infect Dis 2006;6:99.
12. Falagas ME, Bliziotis IA, Mavrogenis AF, Papagelopoulos PJ. Spondylodiscitis after facet
joint steroid injection: a case report and review of the literature. Scand J Infect Dis 2006;38:295-9.
13. Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P. Comparison of mortality
of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 2006;57:1251-4.
14. Michalopoulos A, Falagas ME. Multi-systemic methicillin resistant Staphylococcus aureus
(MRSA) community-acquired infection. Med Sci Monit 2006;12:39-43.
15. Manetas S, Moutzouris DA, Falagas ME. Scalp necrosis: a rare complication of temporal
arteritis. Clin Rheumatol 2006 May 6; [Epub ahead of print].
16. Falagas ME, Bakossi A, Pappas VD, Holevas PV, Bouras A, Stamata E. Secular trends of
blood isolates in patients from a rural area population hospitalized in a tertiary center in a small city in Greece. BMC Microbiol 2006;6:41.
17. Kanavaki S, Mantadakis E, Nikolaou S, Papavassiliou A, Karambela S, Anagnostou S,
Falagas ME, Samonis G. Resistance of Mycobacterium tuberculosis isolates in different populations in Greece during 1993-2002. Int J Tuberc Lung Dis 2006;10:559-64.
18. Vassiloyanakopoulos A, Falagas ME, Allamani M, Michalopoulos A. Aspergillus fumigatus
tricuspid native valve endocarditis in a non intravenous drug user (IVDU). J Med Microbiol 2006;55:635-8.
19. Samonis G, Maraki S, Leventakos K, Spanaki AM, Kateifidis A, Galanakis E, Tselentis Y,
Falagas ME, Mantadakis E. Comparative effect of ertapenem, imipenem, and meropenem on the colonization of the gastrointestinal tract of mice by Candida albicans. Med Mycol 2006;44:233-5.
20. Bliziotis IA, Kapaskelis AM, Kasiakou SK, Falagas ME. Limitations in the management of aortic
graft infections. Annals of Vascular Surgery 2006 May 27; [Epub ahead of print].
21. Falagas ME, Bliziotis I, Kapaskelis AM. Red streaks on the leg. American Family Physician
22. Falagas ME, Valotassiou VJ, Papadouli D, Papadopoulos A, Malamitsi J. 99m Technetium-
ciprofloxacin scintigraphy for the evaluation of spinal infections: A preliminary report. Clinical Orthopedics and Related Research (CORR) 2006;444:34-7.
23. Falagas ME, Papastamataki PA, Bliziotis IA. A bibliometric analysis of research
productivity in Parasitology by different world regions during a 9-year period (1995-2003). BMC Infectious Diseases 2006;6:56.
24. Bliziotis IA, Kasiakou SK, Kapaskelis AM, Falagas ME. Mesh-related infection after hernia
repair: case report of an emerging type of foreign-body related infection. Infection 2006;34:46-8.
25. Michalopoulos A, Geroulanos S, Rosmarakis ES, Falagas ME. Frequency, characteristics,
and predictors of microbiologically documented nosocomial infections after cardiac surgery. Eur J Cardiothoracic Surgery 2006;29:456-60.
26. Soteriades ES, Hadjichristodoulou C, Kremastinou J, Chelvatzoglou FC, Minogiannis PS,
Falagas ME. Health promotion programs related to the Athens 2004 Olympic and Para Olympic games. BMC Public Health 2006;6:47
27. Rafailidis PI, Avramopoulos I, Sapkas G, Falagas ME. Multidrug-resistant tuberculous
spondylodiscitis: need for aggressive management and drug susceptibility testing of Mycobacterium tuberculosis isolates. Journal of Infection 2006;52:e35-7.
28. Rellos K, Falagas ME, Vardakas G, Sermaides G, Michalopoulos A. Outcome of critically
ill ‘oldest old’ patients (age ≥ 90 years) admitted to the Intensive Care Unit. Journal of the American Geriatrics Society 2006;54:110-4.
29. Fragoulis KN, Handrinou E, Papadopoulos V, Dardoufas K, Falagas ME. Delayed effusive
pericarditis and recurrent pleural effusion after radiation treatment for Hodgkin’s disease responsive to per os doxycycline. Eur J Haematol 2006;76:176-9.
30. Soteriades ES, Rosmarakis ES, Paraschakis K, Falagas ME. Research contribution of different
world regions in the top-fifty biomedical journals (1995 – 2002). FASEB J 2006;20:29-34.
31. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity
of intravenous colistin: a prospective evaluation. International Journal of Antimicrobial Agents 2005;26:504-7.
32. Falagas ME, Rosmarakis SE. Recurrent post-sternotomy mediastinitis. Journal of Infection 2005;
33. Michalopoulos A., Falagas ME. A bibliometric analysis of global research production in
Respiratory Medicine. Chest 2005;128:3993-8.
34. Horianopoulou M, Lambropoulos S, Papafragas E, Falagas ME. Effect of aerosolized
colistin on multidrug-resistant Pseudomonas aeruginosa in bronchial secretions of patients without cystic fibrosis. J Chemotherapy 2005;17:536-8.
35. Kasiakou SΚ, Fragoulis K, Tzagarakis G, Mistidis P, Kapaskelis A, Falagas ME. Cure of
multidrug-resistant Acinetobacter baumannii prosthetic material-related orthopaedic infections with intravenous colistin. Microbial Drug Resistance 2005;11:287-9.
36. Hadjichristodoulou C, Soteriades E, Kolonia V, Falagas ME, Pantelopoulos E, Panagakos
G, Mouchtouri V, Kremastinou J. Methodological aspects of a GIS-based environmental health inspection program used in the Athens 2004 Olympic and Para Olympic Games. BMC Public Health 2005;5:93.
37. Soteriades ES, Falagas ME. Comparison of amount of biomedical research originating from
European Union compared with the United States. British Medical Journal (BMJ) 2005;331:192-4.
38. Kasiakou SΚ, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME.
Intravenous colistin for treatment of infections due to multidrug-resistant Gram-negative
bacteria in patients without cystic fibrosis. Antimicrobial Agents and Chemotherapy 2005;49:3136-46.
39. Kasiakou SK, Peppas G, Kapaskelis AM, Falagas ME. Regression of skin lesions of Kyrle’s
disease with clindamycin: implications for an infectious component in the etiology of the disease. Journal of Infection 2005;50:412-6.
40. Michalopoulos A, Bliziotis IA, Rizos M, Falagas ME. Worldwide research productivity in
Critical Care Medicine. Critical Care 2005;9:R258-65.
41. Bliziotis I, Rafailidis P, Vergidis P, Falagas ME. Regression of subcorneal pustular dermatosis
lesions with azithromycin. Journal of Infection 2005;51:E31-4.
42. Bliziotis I, Kasiakou S, Baloyanni M, Falagas ME. A healthy woman with right upper
quadrant discomfort on deep palpation. American Family Physician 2005;71:2353-5.
43. Rosmarakis ES, Kapaskelis AM, Rafailidis PI, Falagas ME. Association between
Wegener’s granulomatosis and increased antithyroid antibodies: Report of two cases and review of the literature. International Journal of Clinical Practice 2005;59:373-5.
44. Rosmarakis ES, Vergidis PI, Soteriades ES, Kasiakou SK, Falagas ME. From conference
abstract to full paper: differences between data presented in conferences and journals. FASEB J 2005;19:673-80.
45. Kasiakou SK, Rafailidis PI, Liaropoulos K, Falagas ME. Cure of post-traumatic recurrent
multiresistant Gram-negative rod meningitis with intraventricular colistin. Journal of Infection 2005;50:348-52.
46. Falagas ME, Bliziotis IA, Kasiakou SΚ, Samonis G, Athanassopoulou P, Michalopoulos A.
Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BioMed Central (BMC) Infectious Diseases 2005;5:24.
47. Falagas ME, Karavasiou AI, Bliziotis I. Estimates of global research productivity in
Virology (1995 – 2003). Journal of Medical Virology 2005;76:229-33.
48. Bliziotis I, Paraschakis K, Vergidis PI, Karavasiou AI, Falagas ME. Worldwide trends in
quantity and quality of published articles in the field of infectious diseases. BioMed Central (BMC) Infectious Diseases 2005;5:16.
49. Rosmarakis ES, Vergidis PI, Soteriades ES, Paraschakis K, Papastamataki PA, Falagas ME.
Estimates of global production in cardiovascular diseases research. International Journal of Cardiology 2005;100:443-9.
50. Vergidis PI, Karavasiou AI, Paraschakis K, Bliziotis I, Falagas ME. A bibliometric analysis
of global trends of research productivity in Microbiology. Eur J Clin Microbiol Infect Dis. 2005;24(5):342-6.
51. Rafailidis PI, Prapas SN, Kasiakou SK, Costeas XF, Falagas ME. Effusive-constrictive
calcific pericarditis associated with Streptococcus salivarious: case report and review of the literature. Cardiology in Review 2005;13:113-7.
52. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment
in patients with ICU-acquired infections due to multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clinical Microbiology and Infection 2005 Feb;11:115-21.
53. Michalopoulos A, Kasiakou SK, Rosmarakis ES, Falagas ME. Cure of multidrug-resistant
Acinetobacter baumannii bacteremia with continuous intravenous infusion of colistin. Scandinavian Journal of Infectious Diseases 2005;37:142-5.
54. Rizos M, Falagas ME, Tsiodras S, Betsou A, Foukas P, Michalopoulos A. Usual interstitial
pneumonia associated with cytomegalovirus infection after percutaneous transluminal
coronary angioplasty. European Journal of Clinical Microbiology and Infectious Diseases 2004;23: 848–50.
55. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SΚ, Michalopoulos A. Toxicity
after prolonged (more than four weeks) administration of intravenous colistin. BioMed Central (BMC) Infectious Diseases 2005;1.
56. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME.
Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Critical Care 2005;9:R53-R59.
57. Kasiakou SK, Rafailidis PI, Rosmarakis ES, Falagas ME. Recurrent omphalitis in adults.
Scandinavian Journal of Gastroenterology 2004;39:1021-4.
58. Falagas ME, Christopoulou M, Rosmarakis ES, Vlastou C. Munchausen’s syndrome
presenting as severe panniculitis. International Journal of Clinical Practice 2004;58:720-2.
59. Papadopoulos E., Papagelopoulos PJ, Savvidou OD, Falagas ME, Sapkas GS, Fragkiadakis
EG. Tuberculous sacroilitis. Orthopedics 2003;26:653-7 and 658-9.
60. Papagelopoulos PJ, Sapkas GS, Kateros KT, Papadakis SA, Vlamis JA, Falagas ME. Halo
pin intracranial penetration and epidural abscess in a patient with a previous cranioplasty. Case report and review of the literature. Spine 2001;26:E463-E467.
61. Snydman DR, Falagas ME, Avery R, Perlino C, Ruthazer R, Freeman R, Rohrer R,
Fairchild R, O’Rourke E, Hibberd P, Werner B. Use of combination cytomegalovirus immune globulin (CMVIG) plus ganciclovir for prophylaxis in CMV seronegative liver transplant recipients of a CMV seropositive donor organ: a multicenter, open-label study. Transplantation Proceedings 2001;33:2571-5.
62. Falagas ME, Siakavellas E, Scheib R. Facial masses. American Family Physician
63. Falagas ME, Siakavellas E, Sapkas G, Eliadis K, Kontaxis A. Echinococcal cyst of the fifth
thoracic vertebra in an otherwise healthy young woman. Clinical Infectious Diseases 2000;30:442-3 and 567-8.
64. DesJardin JA, Falagas ME, Wawrose D, Ruthazer R, Schenkein D, Miller K, Snydman
DR. Clinical utility of blood cultures drawn from indwelling central venous catheters in hospitalized patients with cancer. Annals of Internal Medicine 1999;131:641-7.
65. Freeman R, Giatras I, Falagas ME, Supran S, Freeman R, O’Connor K, Bradley J, Snydman
DR, Delmonico FL. Outcome of transplantation of organs procured from bacteremic or fungemic donors. Transplantation 1999;68:1107-11.
66. DesJardin JA, Gibbons L, Cho E, Supran SE, Falagas ME, Werner BG, Snydman DR.
Human herpes virus-6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. Journal of Infectious Diseases 1998;178:1783-6.
67. Falagas ME, Paya C, Ruthazer R, Badley A, Patel R, Wiesner R, Griffith J, Freeman R,
Rohrer R, Werner BG, Snydman DR. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: A prospective derivation and validation cohort analysis. Transplantation 1998;66:1020-8.
68. Falagas ME, Walker AM, Jick H, Ruthazer R, Griffith J, Snydman DR. Late incidence of
cancer after metronidazole use: a matched metronidazole user/nonuser study. Clinical Infectious Diseases 1998;26:384-8.
69. McGrath D, Falagas ME, Rohrer R, Freeman R, Fairchild R, Colbach G, Snydman DR.
Adenovirus infection in adult orthotopic liver transplant recipients: Incidence and clinical significance. Journal of Infectious Diseases 1998;177:459-62.
70. Engels EA, Falagas ME, Lau J, Bennish ML. Typhoid fever vaccines: A meta-analysis of
studies on efficacy and toxicity. BMJ (British Medical Journal) 1998;316:110-6.
71. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG, and the Boston Center for
Liver Transplantation CMVIG study group. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Annalsof Internal Medicine 1997;126:275-9.
72. Falagas ME, McDermott L, Snydman DR. Effect of pH on in vitro antimicrobial
susceptibility of the Bacteroides fragilis group. Antimicrobial Agents andChemotherapy 1997;41:2047-9.
73. Falagas ME, Arbo M, Ruthazer R, Griffith J, Werner BG, Rohrer R, Freeman R, Lewis D,
Snydman DR. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997;63:1595-601.
74. Falagas ME, Snydman DR, Griffith J, Werner BG, Freeman R, Rohrer R, and the Boston
Center for Liver Transplantation CMVIG study group. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Clinical Infectious Diseases 1997;25:314-7.
75. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG, Freeman R, Rohrer R, and
the Boston Center for Liver Transplantation CMVIG study group. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. Clinical Transplantation 1997;11:432-7.
76. Falagas ME, Snydman DR, Ruthazer R, Werner BG, Griffith J, and the Boston Center for
Liver Transplantation CMVIG study group. Surveillance cultures of blood, urine, and throat specimens are not valuable for predicting cytomegalovirus disease in liver transplant recipients. Clinical Infectious Diseases 1997;24:824-9.
77. George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, Rubin R,
and the Boston Center for Liver Transplantation CMVIG study group. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. American Journal of Medicine 1997;103:106-13.
78. Falagas ME, Barefoot L, Griffith J, Ruthazer R, Snydman DR. Risk factors leading to
clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. European Journal of Clinical Microbiology and Infectious Diseases 1996;15:913-21.
79. Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, and the Boston Center for
Liver Transplantation CMVIG study group. Primary cytomegalovirus infection in liver transplant recipients: Comparison of infections transmitted via donor organs and via transfusions. Clinical Infectious Diseases 1996;23:292-7.
80. Falagas ME, Snydman DR, George MJ, Ruthazer R, Griffith J, Werner BG, Freeman R,
Rohrer R, and the Boston Center for Liver Transplantation CMVIG study group. Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Transplantation 1996;61:1716-20.
81. Falagas ME, Snydman DR, Griffith J, Werner BG, and the Boston Center for Liver
Transplantation CMVIG study group. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Clinical Infectious Diseases 1996;23:468-74.
82. Falagas ME, Klempner MS. Babesiosis in patients with AIDS: A chronic infection
presenting as fever of unknown origin. Clinical Infectious Diseases 1996;22:809-12.
83. Falagas ME, Griffiths J, Perkezes J, Worthington M. Cytomegalovirus colitis mimicking
colonic carcinoma in an HIV-negative patient with chronic renal failure. American Journal of Gastroenterology 1996;91:168-9.
84. Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of
IL-1β, TNFα, and their specific inhibitors in undialyzed chronic renal failure, CAPD, and hemodialysis patients. Kidney International 1994;45:890-6.
85. Pereira BJG, King AJ, Falagas ME, Dinarello CA. Interleukin-1 receptor antagonist (IL-1
Ra): An index of dialysis-induced interleukin-1 production. Nephron 1994;67:358-61.
86. Giamarellou H, Touliatou K, Koratzanis G, Petrikkos G, Kanellakopoulou K, Lelekis M,
Pagona A, Tsagarakis J, Symeonides J, Falagas ME. Nosocomial consequences of antibiotic usage. Scandinavian Journal of Infectious Diseases 1986;49 (Suppl):182-8.
PUBLICATIONS: META-ANALYSES (PEER-REVIEWED) 1. Matthaiou DK, Peppas G, Bliziotis IA, Falagas ME. Ciprofloxacin/metronidazole versus
beta-lactam based treatment of intra-abdominal infections: a meta-analysis of comparative trials. Int J Antimicrob Agents (in press).
2. Falagas ME, Fragoulis KN,Bliziotis IA. Oral rifampin for prevention of S. aureus carriage-
related infections in patients with renal failure: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006 May 16; [Epub ahead of print].
3. Vardakas KZ, Samonis G, Michalopoulos A, Soteriades ES, Falagas ME. Antifungal
prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Critical Care Medicine 2006;34:1216-24.
4. Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycosides in combination with
a β-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 2006;57:639-47.
5. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for
antifungal prophylaxis in neutropenic patients with haematologic malignancies: a meta-analysis of randomized controlled trials. British Journal of Hematology 2005;131:22-8.
6. Vardakas KZ, Soteriades ES, Chrysanthopoulou SA. Papagelopoulos PJ, Falagas ME.
Perioperative anti-infective prophylaxis with teicoplanin compared to cephalosporins in orthopedic and vascular surgery involving prosthetic material. Clinical Microbiology and Infection 2005;11:775-7.
7. Bliziotis IA, Michalopoulos A, Kasiakou SK, Samonis G, Christodoulou C,
Chrysanthopoulou S, Falagas ME. Ciprofloxacin versus an aminoglycoside as combination therapy to a beta lactam for the treatment of febrile neutropenia: a meta-analysis of randomised controlled trials. Mayo Clinic Proceedings 2005;80:1146-56.
8. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME. Continuous
versus intermittent intravenous administration of antibiotics: a meta-analysis of randomized controlled trials. Lancet Infectious Diseases 2005;5:581-9.
9. Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA, Falagas ME. The role of
glycopeptides as part of empirical treatment of febrile neutropenic patients: a meta-analysis of randomized controlled trials. Lancet Infectious Diseases 2005;5:431-9.
10. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of
aminoglycoside/beta-lactam combination therapy versus beta lactam monotherapy on the
emergence of antimicrobial resistance: a meta-analysis of randomised controlled trials. Clinical Infectious Diseases 2005;41:149-58.
PUBLICATIONS: SYSTEMATIC REVIEWS (PEER-REVIEWED)
1. Falagas ME, Kasiakou SK. Local administration of polymyxins into the respiratory tract for
the prevention and treatment of pulmonary infections in patients without cystic fibrosis. Infection (in press).
2. Falagas ME, Kopterides P. Risk factors for the isolation of multidrug resistant (MDR)
Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect (in press).
3. Falagas ME, Vardakas KZ, Athanasiou S. Intravenous heparin in combination with
antibiotics for the treatment of deep vein septic thrombophlebitis: a systematic review. Eur J Pharmacol (in press).
4. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients
with endocarditis: a review of the published evidence. J Antimicrob Chemother (in press).
5. Falagas ME, Betsi GI, Tokas T, Athanasiou S. Probiotics for prevention of recurrent urinary
tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs (in press).
6. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis 2006;6:438-446.
7. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: A systematic
review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006 Jun 14; [Epub ahead of print].
8. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a critical review of the evidence from
old and recent studies. Crit Care 2006;10:R27.
9. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii
infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006;10:R48.
10. Falagas ME, Bliziotis IA. Quinolones for the treatment of human brucellosis: A critical
review of the evidence from microbiological and clinical studies. Antimicrobial Agents and Chemotherapy 2006;50:22-33.
11. Kasiakou SK, Lawrence KR, Choulis N, Falagas ME. Continuous versus intermittent
intravenous administration of antibiotics with time-dependent anti-bacterial action: A systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs 2005;65:2499-511.
PUBLICATIONS: NARRATIVE REVIEWS (PEER-REVIEWED) 1. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and
aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res (in press).
2. Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of recurrent vulvovaginal
candidiasis: a review. J Antimicrob Chemother (in press).
3. Tsiodras S, Falagas ME. Clinical assessment and medical management of spine infections.
Clinical Orthopedics and Related Research (CORR) 2006;444:38-50.
4. Falagas ME, Vergidis PI. Urinary tract infections in patients with urinary diversion.
American Journal of Kidney Diseases 2005;46:1030-7.
5. Michalopoulos A, Rizos M, Falagas ME. Severe community-acquired pneumonia (CAP)
due to atypical pathogens. Current Respiratory MedicineReviews 2005;1:265-71.
6. Falagas ME, Vergidis PI. Irrigation with antibiotic-containing solutions for the prevention
and treatment of infections. Clinical Microbiology and Infection 2005;11:862-7.
7. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of
multidrug-resistant Gram-negative bacterial infections. Clinical Infectious Diseases 2005;40:1333-41.
8. Falagas ME, Kasiakou SK. Mesh-related infections after hernia repair surgery. Clinical Microbiology and Infection 2005;11:3-8.
9. Falagas ME, Vergidis PI. Diseases that masquerade as infectious cellulitis. Annals of Internal Medicine 2005;142:47-55.
10. Falagas ME, Siakavellas E. Bacteroides, Prevotella and Porphyromonas species: a review
of antibiotic resistance and therapeutic options. International Journal of Antimicrobial Agents 2000;15:1-9.
11. Falagas ME, Gorbach SL. Mucopurulent cervicitis and pelvic inflammatory disease. IDCP
guidelines. Infectious Diseases in Clinical Practice 1996;5:6-11.
12. Falagas ME, Gorbach SL. Lyme disease: IDCP guidelines. Infectious Diseases in Clinical
13. Falagas ME, Gorbach SL. Human papilloma virus, sexually transmitted intestinal
infections, ectoparasitic infections, and sexual assault. IDCP guidelines. Infectious Diseases in Clinical Practice 1996;5:85-93.
14. Falagas ME, Gorbach SL. Genital ulcers. IDCP guidelines. Infectious Diseases in Clinical
15. Falagas ME, Gorbach SL. Clindamycin and metronidazole. Medical Clinics of North
16. Falagas ME, Gorbach SL. Urinary tract infections: Practice guidelines. Infectious Diseases in Clinical Practice 1995;4:241-57.
17. Falagas ME, Snydman DR. Recurrent cytomegalovirus disease in solid-organ transplant
recipients. Transplantation Proceedings 1995;27(Suppl 1):34-37.
18. Falagas ME, Gorbach SL. Prostatitis, epididymitis, and urethritis: Practice guidelines.
Infectious Diseases in Clinical Practice 1995;4:325-33.
PUBLICATIONS: ESSAYS (PEER-REVIEWED) 1. Falagas ME, Kavvadia P. Eigenlob: author self-citation in leading journals. FASEB J
2. Falagas ME, Zarkadoulia E, Samonis G. Arab science during the golden age and today.
PUBLICATIONS: EDITORIALS - COMMENTARIES (PEER-REVIEWED) 3. Falagas ME, Bliziotis IA. Cost-effectiveness of various research designs: an overlooked
parameter in clinical research. J Clin Epidemiol (in press).
4. Falagas ME, Vardakas KZ. Anti-cytomegalovirus (CMV) prophylaxis in solid organ
transplant recipients. Clinical Microbiology and Infection 2006;12:603-5.
5. Falagas ME, Michalopoulos A. Polymyxins: old antibiotics are back. Lancet 2006;367:633-
6. Papagelopoulos PJ, Falagas ME. Editorial comment. Clin Orthop Relat Res 2006;444:2-3. 7. Papadimitropoulos V, Vergidis PI, Bliziotis I, Falagas ME. Vaccination against typhoid
fever in travelers: a cost-effectiveness approach. Clinical Microbiology and Infection 2004;10:681-83.
PUBLICATIONS: ORIGINAL RESEARCH - LETTERS TO THE EDITOR (PEER- REVIEWED) 1. Panos G, Kopterides P, Falagas ME. Hyperlactatemia due to nevirapine, a non-nucleoside reverse
transcriptase inhibitor (NNRTI). Ann Intern Med (in press).
2. Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: a meta-
analysis of randomized controlled trials. J Am Acad Dermatol (in press).
3. Michalopoulos A, Gregoriades K, Falagas ME. Effect of different arrangements of T-piece parts
on oxygenation of patients with tracheostomy. Anesth Analg (in press).
4. Fragoulis KN, Christodoulou C, Falagas ME. Tibia pain and purple-colored lesion. Am J Med (in
5. Panos GZ, Lampropoulos KM Angelousi AG, Charatsis GG, Falagas ME. Lamivudine and
famciclovir treatment in HIV patients with acute hepatitis B virus infection and hepatitis B reactivation: a case series analysis. J Clin Gastroenterol (in press).
6. Peppas G, Fragoulis KN, Falagas ME. Successful conservative management of large splenic
infarcts. Journal of Gastroenterology and Hepatology (in press).
7. Falagas ME, Zouglakis GM, Kavvadia PK. How masked is the “masked peer-review”
of abstracts submitted to international medical conferences? Mayo Clin Proc 2006;81:705.
8. Falagas ME, and Vardakas KZ. Liposomal amphotericin B as antifungal prophylaxis in bone
marrow transplant patients. Am J Hematol 2006;81:299-300.
9. Michalopoulos A, Falagas ME. The ingredients of a successful donation by brain death
program in Greece. Am J Transplant 2006;6:642-3.
10. Michalopoulos A, Prapas S, Falagas ME. The incidence of adult respiratory distress
syndrome in patients undergoing off-pump coronary artery bypass grafting surgery. Eur J Anaesthesiol 2006;23:80.
11. Samonis G, Kofteridis DP, Maraki S, Alegakis D, Mantadakis E, Papadakis JA, Gikas A,
Falagas ME. Levofloxacin and moxifloxacin increase the human gut colonization by Candida species. Antimicrobial Agents Chemother 2005;49:5189.
12. Kondilis BK, Soteriades ES, Falagas ME. Health literacy research in Europe: a snapshot.
13. Falagas ME, Fabritsi E, Chelvatzoglou FC, Rellos K. Penetration of the English language in
science: the case of a German national interdisciplinary critical care conference. Critical Care 2005;9:655-6.
14. Falagas ME, Fragoulis KN, Kopterides P. An analysis of the published Massachusetts
General Hospital case records (1994 –2004). American Journal of Medicine 2005;118:1452-3.
15. Fragoulis KN, Klouvas GD, Falagas ME. Impetigo-like vegetating nasal lesions caused by
Klebsiella pneumoniae. American Journal of Medicine 2005;118: 925-7.
16. Rosmarakis ES, Kapaskelis AM, Rafailidis PI, Falagas ME. Wegener’s syndrome presenting
as unresponsive pulmonary infection. American Family Physician 2005;71:1062-4.
PUBLICATIONS: COMMENT - LETTERS TO THE EDITOR (PEER-REVIEWED) 1. Kopterides P, Falagas ME. Can pneumococcal conjugate vaccine use lead to “collateral
damage”? N Engl J Med (in press).
2. Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii
infections in critically ill patients. Clin Infect Dis (in press).
3. Falagas ME, Kasiakou SK, Michalopoulos A. Polymyxins: a word of caution for prudent use
of valuable “old antibiotics”. Infect Control Hosp Epidemiol (in press).
4. Falagas ME, Kasiakou SK. Use of international units when dosing colistin will help
decrease confusion related to various formulations of the drug around the world. Antimicrob Agents Chemother 2006;50:2274-5.
5. Falagas ME, Kiriaze IJ. Reaction to the threat of influenza pandemic: the mass media and
the public. Crit Care 2006;10:408.
6. Falagas ME. Unique author identification number in scientific databases: a suggestion. PLoS
7. Falagas ME, Kasiakou SK. Correct use of the term pandrug-resistant (PDR) Gram-negative
bacteria. Clinical Microbiology and Infection 2005;11:1049-50.
8. Michalopoulos A, Kasiakou SΚ, Falagas ME. The significance of different formulations of
aerosolized colistin. Critical Care 2005;9:417-8.
9. Falagas ME, Kasiakou SK, Michalopoulos A. Treatment of multidrug-resistantPseudomonas aeruginosa and Acinetobacter baumannii pneumonia. Journal of Cystic Fibrosis 2005;4:149-50.
10. Falagas ME, Kasiakou SK, Michalopoulos A. Antimicrobial resistance of Acinetobacter
spp. in Europe. Clinical Microbiology and Infection 2004;10:1106-7.
11. Falagas ME, Vergidis PI. Addressing the limitations of structured abstracts. Annals of Internal Medicine 2004;141:576-7.
12. Engels EA, Falagas ME, Lau J, Bennish MI. Typhoid fever vaccines. Vaccine
13. Falagas ME. Monotherapy versus β-lactam/aminoglycoside combination treatment for
Gram-negative bacteremia. Antimicrobial Agents and Chemotherapy 1997; 41:2593-2594.
14. Snydman DR, Falagas ME. Cytomegalovirus prevention in transplant recipients. Lancet PUBLICATIONS: REPLY - LETTERS TO THE EDITOR 1. Falagas ME, Kasiakou SK. Continuous intravenous administration of antibiotics. Lancet Infectious Diseases 2006;6:259-260.
2. Falagas ME, Matthaiou DK, Bliziotis IA. Aminoglycosides in combination with a {beta}-
lactam for the treatment of bacterial endocarditis: authors' response. J Antimicrob Chemother 2006;57:1255-6.
3. Falagas ME, Vardakas KZ, Michalopoulos A. In meta-analysis itraconazole is superior to
fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy - response to Prentice et al. Br J Haematol 2006;132:658-9.
4. Falagas ME, Bliziotis IA. Effect of aminoglycoside/beta-lactam combination therapy versus
beta lactam monotherapy on the emergence of antimicrobial resistance. Clin Infect Dis 2005;41:1543-4.
5. Falagas ME, Christopoulou M, Rosmarakis ES, Vlastou C. Munchausen's syndrome
presenting as severe panniculitis. International Journal of Clinical Practice 2005;59:505.
6. Falagas ME, Snydman DR. Cytomegalovirus and mortality of liver transplant recipients in
the 1990s. Annals of Internal Medicine 1997;127:412.
PUBLICATIONS: GROUP AUTHORSHIP - ORIGINAL RESEARCH PAPERS (PEER- REVIEWED) 1. Charbonnel B, et al. Pioglitazone elicits long-term improvements in insulin sensitivity in
patients with type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia 2005;48:553–560.
2. Belcher G, et al. Changes in liver tests during 1-year treatment of patients with type 2
diabetes with pioglitazone, metformin or gliclazide. Diabet Med 2005;22:973-9.
3. Betteridge DJ, Verges B. Long-term effects on lipids and lipoproteins of pioglitazone versus
gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 2005;48:2477-81.
4. Roden M, et al. Long-term effects of pioglitazone and metformin on insulin sensitivity in
patients with type 2 diabetes mellitus. Diabet Med 2005;22:1101-6.
5. Matthews DR, et al. Long-term therapy with addition of pioglitazone to metformin
compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2004;21:167-74.
6. Belcher G, et al. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone,
metformin and gliclazide. Int J Clin Pract 2004;58:833-7.
7. Schernthaner G, et al. Efficacy and safety of pioglitazone versus metformin in patients with
type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76.
8. Charbonnel B, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to
failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093-104.
9. Bouza E, et al. A European perspective on nosocomial urinary tract infections II. Report on
incidence, clinical characteristics and outcome (ESGNI-004 study). Clin Microbiol Infect 2001;7:532-42.
10. Bouza E, e al. A European perspective on nosocomial urinary tract infections I. Report on
the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). Clin Microb Infect 2001;7:523-31.
BOOKS 1. Gorbach SL, Falagas ME (editors). 5-Minute Infectious Diseases Consult (textbook), 1st
edition. Lippincott Williams and Wilkins, Philadephia, Pensylvania, 2001.
2. Gorbach SL, Bartlett JG, Falagas ME, Hamer D. Guidelines for Infectious Diseases in Primary Care (handbook). Lippincott Williams and Wilkins, Philadelphia, Pensylvania, 1999.
BOOK CHAPTERS 1. Falagas ME, Apostolou K. Mechanisms of inflammation in the intervertebral disc. In: Diseases of Spine. Sapkas E (ed), Kafkas Co., Athens, Greece, (in press).
2. Falagas ME, Choulis N, Michalopoulos A. Polymyxins. In: Antimicrobial Therapy (2nd web
edition, www.antimicrobe.org). Yu V (ed), Apple Trees Productions, LCC, New York, New York, 2005.
3. Falagas ME, Kasiakou S. Emergency management of neutropenic patients with fever. In:
Emergency management of infectious diseases. Seitanidis B, Georgilis K (eds). Beta Co., Athens, Greece, 2003, pages, 51-72.
4. Falagas ME. Modern management of neutropenic patients with fever. In: Lymperatos K, et
al (eds). Developments in Internal Medicine, Hygeia Hospital Publications, Athens, Greece, 2001, pages 327-346.
5. Snydman DR, Falagas ME. Infection control in solid organ-transplant recipients. In:
Abrutyn E, Goldmann D, Scheckler WE (eds). Saunders Infection Control Reference Service, 2nd edition, W.B. Saunders Co., Philadelphia, Pennsylvania, 2001, pages 757-769.
6. Snydman DR, Falagas ME. Infection control in solid organ-transplant recipients. In:
Abrutyn E, Goldmann D, Scheckler WE (eds). Saunders Infection Control Reference Service, 1st edition, W.B. Saunders Co., Philadelphia, Pennsylvania, 1998, pages 631-636.
7. Falagas ME, Gorbach SL. Traveler’s diarrhea. In: LaMont TJ (ed). Gastrointestinal Infections: Diagnosis and management, Marcel Dekker Inc., New York, 1997, pages 125-148.
ABSTRACTS (selection of original research abstracts from international scientific meetings) 1. Kasiakou S, Lawrence K, Choulis N, Falagas ME. Continuous versus intermittent
intravenous administration of antibiotics with time-dependent anti-bacterial action: a systematic review of pharmacokinetic and pharmacodynamic parameters. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
2. Horianopoulou M, Legakis N, Kanellopoulou M, Lambropoulos S, Tsakris A, Falagas ME.
Frequency and predictors of colonisation of the respiratory tract by Gram-negative bacteria with the blaVIM gene in patients of a newly established intensive care unit. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
3. Falagas ME, Siempos I, Bliziotis I, Rellos K, Michalopoulos A. Administration of
antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
4. Rafailidis P, Kasiakou S, Morfou P, Georgoulias G, Nikita D, Falagas ME. Secular trends of
antimicrobial resistance of blood isolates in a newly founded Greek hospital. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
5. Falagas ME, Fragoulis K, Bliziotis I, Chatzinikolaou I. Rifampin and minocycline
impregnated central venous catheters: a meta-analysis of randomised controlled trials assessing catheter colonisation and catheter-related bloodstream infection. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
6. Kopterides P, Koletsi P, Morfou P, Rellos K, Mastora Z, Rizos M, Falagas ME. Exposure to
fluoroquinolones is a risk factor for polymyxin-only susceptible Acinetobacter baumannii bacteraemia. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
7. Koletsi P, Kopterides P, Michalopoulos A, Mastora Z, Rellos K, Falagas ME. Risk factors
for polymyxin-only susceptible Pseudomonas aeruginosa bacteraemia. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
8. Falagas ME, Matthaiou D, Papastamataki P, Bliziotis I. The role of aminoglycosides in
combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
9. Falagas ME, Bliziotis I, Michalopoulos A, Sermaides G, Papaioannou V, Nikita D, Choulis
N. Effect of a policy for restriction of selected classes of antibiotics on antimicrobial drug cost and resistance. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
10. Falagas ME, Fragoulis K, Kasiakou S, Sermaides G, Michalopoulos A. Nephrotoxicity of
intravenous colistin: a prospective evaluation. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
11. Falagas ME, Karydis I, Georgoulias G, Hatzopoulou P, Nikita D, Kostogiannou I.
Needlestick and sharp injuries of health care personnel in a newly founded tertiary hospital: a prospective study. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
12. Falagas ME, Fragoulis K, Zouglakis G, Karydis I. A comparative study on the cost of new
drugs in different therapeutic categories. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
13. Falagas ME, Bliziotis I, Kondilis B, Papastamataki P, Zouglakis G, Soteriades E. Eighteen
years of research on AIDS: contribution of and collaborations between different world regions. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
14. Kofterides D, Falagas ME, Kavvadia P, Mantadakis E, Bliziotis I, Saloustros E, Maraki S,
Samonis G. Morganella morganii infections in a general tertiary hospital. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006.
15. Kofteridis D, Falagas ME, Kasiakou S, Roditakis G, Alegakis D, Samonis G. Hospital-
acquired multidrug resistant Gram-negative infections: Clinical features, treatment and outcome. 45th Interscience Conference on Antimicrobial Agents andChemotherapy (ICAAC), Washington, DC, December, 2005.
16. Michalopoulos A, Falagas ME, Rellos K, Papadimitriou L, Geroulanos S, Kotsis V, Karatza
D, Prapas S. Is cardiopulmonary bypass a risk factor for ARDS in patients undergoing CABG surgery? 18th Annual Congress of the European Society of Intensive Care Medicine (ESICM), Amsterdam, Nederlands, September 2005.
17. Michalopoulos A, Bliziotis I, Rizos M, Rellos K, Dimitriadou E, Boursinos V, Falagas ME.
Worldwide research productivity in Critical Care. 18th Annual Congress of the European Society of Intensive Care Medicine (ESICM), Amsterdam, Nederlands, September 2005.
18. Michalopoulos A, Vardakas K, Samonis G, Nikita D, Soteriades E, Rellos K, Falagas ME.
Antifungal prophylaxis with azoles in high-risk, surgical ICU patients: a meta-analysis. 18th Annual Congress of the European Society of Intensive Care Medicine (ESICM), Amsterdam, Nederlands, September 2005.
19. Michalopoulos A, Prapas S, Geroulanos S, Rellos K, Rizos M, Nikita D, Georgoulias G,
Falagas ME. Candidemia in patients undergoing CABG surgery with and without cardiopulmonary bypass. 18th Annual Congress of the European Society of Intensive Care Medicine (ESICM), Amsterdam, Nederlands, September 2005.
20. Rellos K, Falagas ME, Vardakas K, Sermaides G, Fotakis D, Papacharalabous V,
Michalopoulos A. Outcome of critically “oldest old” patients (age ≥ 90 years) admitted to the ICU. 18th Annual Congress of the European Society of Intensive Care Medicine (ESICM), Amsterdam, Nederlands, September 2005.
21. Falagas ME, Rizos M, Bliziotis I, Kasiakou SK, Michalopoulos A. Toxicity after prolonged
(more than four weeks) administration of intravenous colistin. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
22. Bliziotis I, Peppas G, Rafailidis P, Vergidis PI, Kapaskelis A, Papastamataki PA, Falagas
ME. Peripheral T-cell lymphoma masquerading as cellulitis. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
23. Falagas ME, Bliziotis I, Mavrogenis A, Antoniou D, Papagelopoulos PJ. Spondylodiscitis
after facet joint steroid injection. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
24. Kasiakou SK, Rosmarakis E, Peppas G, Kapaskelis A, Sergounioti A, Falagas ME.
Regression of skin lesions of Kyrle’s disease with clyndamycin: implications for an infectious component in the aetiology of the disease. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
25. Kasiakou SK, Sermaides G, Michalopoulos A, Soteriades E, Falagas ME. Continuous
versus intermittent administration of antibiotics: a meta-analysis of randomised controlled trials. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
26. Kasiakou SK, Michalopoulos A, Rosmarakis E, Vergidis PI, Falagas ME. Cure of
multidrug-resistant (MDR) Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
27. Vardakas K, Soteriades E, Chrysanthopoulou S, Papagelopoulos PJ, Falagas ME.
Perioperative anti-infective prophylaxis with teicoplanin or second generation cephalosporins in vascular and orthopaedic surgery involving prosthetic material: a meta-analysis of randomised controlled trials. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
28. Bliziotis I, Samonis G, Vardakas K, Chrysanthopoulou S, Falagas ME. Effect of
aminoglycoside/beta-lactam combination therapy versus beta lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomised controlled trials. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
29. Bliziotis I, Michalopoulos A, Kasiakou SK, Samonis G, Christodoulou C,
Chrysanthopoulou S, Falagas ME. Ciprofloxacin versus an aminoglycoside as combination therapy to a beta lactam for the treatment of febrile neutropenia: a meta-analysis of randomised controlled trials. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
30. Bliziotis I, Paraschakis K, Vergidis PI, Karavasiou AI, Kapaskelis A, Falagas ME.
Worldwide trends in quality of published articles in the field of Infectious Diseases. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
31. Kasiakou SK, Fragoulis K, Tzagarakis G, Mistidis P, Kapaskelis A, Falagas ME. Cure of
multidrug-resistant Acinetobacter baumannii prosthetic material-related orthopaedic infections with intravenous colistin. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
32. Kasiakou SK, Rafailidis P, Liaropoulos K, Bliziotis I, Chelvatzoglou F, Falagas ME. Cure
of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intravenrticular colistin. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
33. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis A, Falagas ME.
Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
34. Kasiakou SK, Michalopoulos A, Soteriades E, Samonis G, Sermaides G, Falagas ME.
Intravenous colistin for treatment of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
35. Vergidis PI, Karavasiou AI, Paraschakis K, Bliziotis I, Papastamataki PA, Falagas ME. A
bibliometric analysis of worldwide trends in research productivity in Microbiology. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
36. Rosmarakis E, Vergidis PI, Kapaskelis A, Paraschakis K, Falagas ME. From conference
abstract to full paper: differences between data resented in conferences and journals. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
37. Falagas ME, Rizos M, Tsiodras S, Betsou A, Foukas P, Michalopoulos A. Usual interstitial
pneumonia associated with cytomegalovirus infection after percutaneous transluminal coronary angioplasty. 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 2005.
38. Rellos K, Georgoulias G, Karatza DC, Mastora Z, Boursinos V, Falagas ME,
Michalopoulos A. Bacteraemia in Intensive Care Unit patients of a new general hospital. 7th German Interdisciplinary Conference of Intensive Care Medicine, Hamburg, Germany, December 2004.
39. Falagas ME, Tsiodras S, Rellos K, Mentzelopoulos S, Kasiakou S, Michalopoulos A.
Effectiveness and safety of colistin treatment in patients with ICU-acquired infections due
to multiresistant gram-negative bacteria: the renaissance of an old antibiotic. 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, Massachusetts, September 2004.
40. Kasiakou SK, Kapaskelis AM, Paraschakis K, Chelvatzoglou FC, Sergounioti AE, Falagas
ME. Continuous versus intermittent intravenous administration of antibiotics: a systematic review of clinical trials. 42nd Annual Meeting of IDSA, Boston, Massachusetts, September 2004.
41. Barinaga JL, Falagas ME, Hadley S, Nasraway SA, Selker HP, Snydman DR. Systemic
antifungal forprophylaxis of invasive Candida infections in surgical intensive care unit patients. 41st Interscience Conference on Antimicrobial Agents andChemotherapy (ICAAC), Chicago, Illinois, September 2001.
42. Avramopoulos I, Gatsiou C, Nikolidaki C, Feloukas T, Geromeriati K, Vakalis N,
Achimastos A, Nasioulas G, Falagas ME. Streptococcus agalactiae infections in non-pregnant adults: Single center experience of a growing clinical problem. 11th European Congress of Clinical Microbiology and Infectious Diseases(ECCMID), Istanbul, Turkey, April 2001.
43. Avramopoulos I, Vakalis N, Sapkas G, Christopoulou M, Xinotroulas I, Nikolidaki C,
Achimastos A, Falagas ME. Multidrug-resistant tuberculous spondylodiscitis: Growing evidence for the need of aggressive management of spondylodiscitis and drug susceptibility testing of Mycobacterium tubeculosis isolates. 11thEuropean Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Istanbul, Turkey, April 2001.
44. Falagas ME, Papadimitropoulos V. Vaccination against typhoid fever in travelers: a cost-
effectiveness approach. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, California, September 1999.
45. Falagas ME, Kosmopoulou O, Christodoulou C, Skarlos D. Treatment of neutropenic
patients with fever in an outpatient setting. 21st International Congress of Chemotherapy (ICC), Birmingham, England, July 1999.
46. Snydman DR, Falagas ME, Freeman R, Avery R. Cytomegalovirus immune globulin plus
intravenous ganciclovir to prevent primary cytomegalovirus disease in liver transplants. 17h world congress of the Transplantation Society, Montreal, Canada, July 1998.
47. DesJardin J, Falagas ME, McDermott L, Snydman DR. In vitro synergy between
trovafloxacin or ciprofloxacin and cefoperazone, ceftazidime, ticarcillin-clavulanic acid, or trimethoprim-sulfamethoxazole against Stenotrophomonas maltophilia. 8th International Congress of the International Infectious Diseases Society, Boston, Massachusetts, May 1998.
48. Giatras I, Falagas ME, Supran S, Freeman R, O’Connor K, Bradley J, Snydman DR,
Delmonico FL. Outcome of transplantation of organs procured from bacteremic or fungemic donors. 24th annual meeting of the American Society ofTransplant Surgeons (ASTS), Chicago, Illinois, May 1998.
49. Falagas ME, Paya C, Ruthazer R, Badley A, Patel R, Wiesner R, Griffith J, Freeman R,
Rohrer R, Snydman DR. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: A derivation and validation cohort analysis. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy(ICAAC), Toronto, Canada, September 1997.
50. Falagas ME, MacDermott L, Snydman DR. The effect of pH on the in vitro susceptibility
of Bacteroides fragilis group. 37th InterscienceConference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, September 1997.
51. DesJardin JA, Falagas ME, Warrose D, Ruthazer R, Snydman DR. Utilization of
indwelling central venous catheters for obtaining blood cultures in hospitalized oncology patients: service or disservice. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, September 1997.
52. DesJardin JA, Falagas ME, Gibbons L, Levy S, Ablashi DV, Werner B, Snydman DR.
Human herpes virus 6 (HHV-6) infection is associated with development of primary cytomegalovirus infection and disease in kidney transplantation. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, September 1997.
53. Falagas ME, Arbo M, Ruthazer R, Griffith J, Freeman R, Rohrer R, Lewis D, Snydman DR.
The impact of cytomegalovirus on cost and first post-transplant year hospital length of stay among liver transplant recipients. 16th annual meeting of the American Society of Transplant Physicians (ASTP), Chicago, Illinois, May 1997.
54. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG, Freeman R, Rohrer R, and
the Boston Center for Liver Transplantation CMVIG study group Cytomegalovirus Immune Globulin (CMVIG) is associated with improved one-year and long-term survival in orthotopic liver transplant recipients. 16th annual meeting of the American Society of Transplant Physicians (ASTP), Abstract # 254, Chicago, Illinois, May 1997.
55. Engels E, Falagas ME, Schmidt C, Lau J, Bennish M. Efficacy of typhoid fever vaccines: A
meta-analysis. BioMedicine 1997, Tri-Society meeting, Washington, DC, May 1997.
56. Falagas ME, Soteriades E, Mantzoros C. Greek biomedical scientists in diaspora: a national
resource. Foundation of a database of Greek biomedical scientists in diaspora. 4th World Biomedical Conference of the Hellenic Diaspora, Nicosia, Cyprus, October 1996.
57. Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, and the Boston Center for
Liver Transplantation CMVIG study group. Primary cytomegalovirus infection in liver transplantation: Comparison between donor and transfusion transmitted infection. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, Louisiana, September 1996.
58. Falagas ME, Snydman DR, Ruthazer R, Werner BG, Griffith J, and the Boston Center for
Liver Transplantation CMVIG study group. Lack of value of surveillance blood, urine, and throat cytomegalovirus cultures in predicting cytomegalovirus disease in liver transplant recipients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, Louisiana, September 1996.
59. McGrath D, Falagas ME, Rohrer R, Freeman R, Snydman DR. Adenoviral infections in
adult orthotopic liver transplant recipients: Prevalence and clinical significance. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, Louisiana, September 1996.
60. Falagas ME, Walker AM, Jick H, Ruthazer R, Griffith J, Snydman DR. Cancer incidence
after metronidazole use: A matched metronidazole user/non-user study of 60,054 subjects. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, Louisiana, September 1996.
61. Falagas ME, Barefoot L, Griffith J, Ruthazer R, Snydman DR. Risk factors for clinical
failure of antibiotic therapy in patients with intra-abdominal or skin/soft tissue infections
treated with cefotetan, cefoxitin, or ampicillin/sulbactam monotherapy: A retrospective controlled study. 1st European Congress of Chemotherapy, Glasgow, Scotland, May 1996.
62. Falagas ME, Snydman DR, Griffith J, Werner BG, Freeman R, Rohrer R, and the Boston
Center for Liver Transplantation CMVIG study group. Predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, California, September 1995.
63. Falagas ME, Snydman DR, Griffith J, Werner BG, and the Boston Center for Liver
Transplantation CMVIG study group. Cytomegalovirus exposure from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, California, September 1995.
64. Pereira BJG, King AJ, Falagas ME, Shapiro L, Strom JA, Dinarello CA. Plasma cytokine
levels in undialyzed chronic renal failure, CAPD, and hemodialysis patients reflect residual renal function. 12th International Congress of Nephrology, Jerusalem, Israel, June 1993.
REFERENCES 1. Sherwood Gorbach, MD
Professor of Medicine and Family Medicine, and Community Health Tufts University School of Medicine 136 Harrison Avenue, Boston, Massachusetts 02111 Tel: +1-617-636-5811, e-mail: [email protected]
Past Dean, Tufts University School of Medicine 145 Harrison Avenue, Boston, Massachusetts 02111 Tel: +1-617-636-6800, e-mail: [email protected]
Professor of Medicine, Boston University School of Medicine Director, International Health Center 715 Albany Street, Boston, Massachusetts Tel: +1-617-638-5234, e-mail: [email protected]
Professor of Medicine and Pathology, Tufts University School of Medicine Chief, Division of Infectious Diseases, New England Medical Center 750 Washington Street, Box 238, Boston, Massachusetts 02111 Tel: +1-617-636-5788, e-mail: [email protected]
5. Dimitris Trichopoulos, MD, DSc
Vincent L. Gregory Professor of Cancer Prevention, Department of Epidemiology, Harvard School of Public Health Professor of Epidemiology, Athens University School of Medicine 75 Mikras Asias Street, Athens, Greece Tel: +30-210-746-2012, e-mail: dimitri@ hsph.harvard.edu
Adjunct Professor of Epidemiology, Harvard University 667 Huntington Avenue, Boston, Massachusetts, 02115 Tel: +1-617-432-4565, e-mail: [email protected]
Page 1 of 6 Permarock Joint Adhesive (PU) Permarock Joint Adhesive (PU) Safety Data Sheet according to HSNO Regulations SECTION 1 Identification of the substance / mixture and of the company / undertaking Product Identifier Product name: Chemical Name: Synonyms: Proper shipping name: Chemical formula: Other means of identification: CAS number: Relevant iden
USING MEDICATION in treating psychological or psychiatric complaints Gebruik van medicijnen bij psychische of psychiatrische klachten Stichting Pandora, 2e Constantijn Huygensstraat 77, 1054 CS Amsterdam, tel 020-6851171 www.stichtingpandora.nl / www.zogeknogniet.nl / www.medicijnwijzer.nl WARNING: This Information was written in 2003. A great deal of the user- information is